CD5L as a promising biological therapeutic for treating sepsis

Liliana Oliveira, M. Carolina Silva, Ana P. Gomes, Rita F. Santos, Marcos S. Cardoso, Ana Nóvoa, Hervé Luche, Bruno Cavadas, Irina Amorim, Fátima Gärtner, Bernard Malissen, Moisés Mallo and Alexandre M. Carmo ()
Additional contact information
Liliana Oliveira: Universidade do Porto
M. Carolina Silva: Universidade do Porto
Ana P. Gomes: Universidade do Porto
Rita F. Santos: Universidade do Porto
Marcos S. Cardoso: Universidade do Porto
Ana Nóvoa: Instituto Gulbenkian de Ciência
Hervé Luche: CNRS
Bruno Cavadas: Universidade do Porto
Irina Amorim: Universidade do Porto
Fátima Gärtner: Universidade do Porto
Bernard Malissen: CNRS
Moisés Mallo: Instituto Gulbenkian de Ciência
Alexandre M. Carmo: Universidade do Porto

Nature Communications, 2024, vol. 15, issue 1, 1-21

Abstract: Abstract Sepsis results from systemic, dysregulated inflammatory responses to infection, culminating in multiple organ failure. Here, we demonstrate the utility of CD5L for treating experimental sepsis caused by cecal ligation and puncture (CLP). We show that CD5L’s important features include its ability to enhance neutrophil recruitment and activation by increasing circulating levels of CXCL1, and to promote neutrophil phagocytosis. CD5L-deficient mice exhibit impaired neutrophil recruitment and compromised bacterial control, rendering them susceptible to attenuated CLP. CD5L-/- peritoneal cells from mice subjected to medium-grade CLP exhibit a heightened pro-inflammatory transcriptional profile, reflecting a loss of control of the immune response to the infection. Intravenous administration of recombinant CD5L (rCD5L) in immunocompetent C57BL/6 wild-type (WT) mice significantly ameliorates measures of disease in the setting of high-grade CLP-induced sepsis. Furthermore, rCD5L lowers endotoxin and damage-associated molecular pattern (DAMP) levels, and protects WT mice from LPS-induced endotoxic shock. These findings warrant the investigation of rCD5L as a possible treatment for sepsis in humans.

Date: 2024
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-024-48360-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48360-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-48360-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().